{"id":"W4367296748","doi":"10.1016/j.eururo.2023.03.030","title":"Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Javelin; Avelumab; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Carcinoma; Chemotherapy; Clinical trial; Bladder cancer; Urology; Immunotherapy; Pembrolizumab; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005252848,0.0004012903,0.0008053001,0.0000992303,0.0002743639,0.00002656309,0.0003824878,0.0001311341,0.0003659667],"category_scores_gemma":[0.0004489944,0.0002601006,0.0005421346,0.0003234264,0.0003587718,0.0000546385,0.0001140126,0.0004244353,0.00059317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003856626,"about_ca_system_score_gemma":0.0001718756,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001333386,"about_ca_topic_score_gemma":0.00005235412,"domain_scores_codex":[0.9966676,0.0007361174,0.0008552446,0.000845513,0.000261467,0.0006340539],"domain_scores_gemma":[0.9968376,0.001658436,0.000252227,0.0008203179,0.0002282721,0.0002032184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6864613,0.004390487,0.007825945,0.00004138144,0.003750086,0.001851923,0.00223935,0.0002788991,0.008493399,0.0001701185,0.1109588,0.1735384],"study_design_scores_gemma":[0.454731,0.02033081,0.0685979,0.00002412753,0.0008850495,0.00004490505,0.0002075015,0.001188408,0.0007896175,0.0004012525,0.4523228,0.0004765975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819213,0.001531259,0.001595968,0.007762669,0.002155025,0.002849286,0.0006278621,0.000265589,0.001291021],"genre_scores_gemma":[0.982082,0.001269065,0.000299091,0.01020946,0.00390608,0.0001748535,0.0005373294,0.0001404024,0.001381688],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3413641,"threshold_uncertainty_score":0.9999851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1709709398084595,"score_gpt":0.4281932307307954,"score_spread":0.2572222909223359,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}